Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.
Pemmaraju, N, Kantarjian, H, Andreeff, M, Cortes, J, Ravandi, F
Kazi, JU, Rönnstrand, L
© 2021 Reactome